Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Expert Opinion on Drug Safety|January 16, 2010
PM101: intravenous amiodarone formulation changes can improve medication safetyPaul F Souney, Warren D Cooper, Daniel J CushingClinical and Experimental Pharmacology & Physiology|October 2, 2009
The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion periodDaniel J Cushing, Warren D Cooper, Michael R Gralinski, et al.Journal of Clinical Pharmacology|January 25, 2011
Comparative bioavailability of a premixed, ready-to-use formulation of intravenous amiodarone with traditional admixture in healthy subjectsDaniel J Cushing, Michael P Adams, Warren D Cooper, et al.Journal of Clinical Pharmacology|February 28, 2009
Bioequivalence of 2 intravenous amiodarone formulations in healthy participantsDaniel J Cushing, Michael P Adams, Warren D Cooper, et al.The American Journal of Cardiology|October 6, 2009
Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humansDaniel J Cushing, Michael P Adams, Warren D Cooper, et al.European Journal of Pharmacology|February 24, 2009
PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effectsDaniel J Cushing, Peter R Kowey, Warren D Cooper, et al.Cardiovascular Toxicology|June 26, 2009
Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogsDaniel J Cushing, Warren D Cooper, Michael R Gralinski, et al.European Journal of Pharmacology|March 24, 2010
Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonistDaniel J Cushing, Warren D Cooper, Marlene L Cohen, et al.Clinical and Experimental Pharmacology & Physiology|September 22, 2011
Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humansDaniel J Cushing, Paul F Souney, Warren D Cooper, et al.Pageof 1